Literature DB >> 1535676

Liver pathology associated with the use of anabolic-androgenic steroids.

K L Søe1, M Søe, C Gluud.   

Abstract

This review examines the liver-damaging side effects of anabolic-androgenic steroids (AAS). It seems that AAS can cause development of peliosis hepatis, subcellular changes of hepatocytes, hepatocellular hyperplasia and hepatocellular adenomas. On the other hand, it has not been convincingly proved that AAS can cause development of hepatocellular carcinomas when used in the usual therapeutic doses. Tumours reported as hepatocellular carcinomas caused by AAS seems to be hyperplastic lesions of a benign nature able to regress with withdrawal of the putative agent. The effects of untraditional combinations and high-dose AAS are not yet known, leaving the possibility of a carcinogenic effect in those cases.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1535676     DOI: 10.1111/j.1600-0676.1992.tb00560.x

Source DB:  PubMed          Journal:  Liver        ISSN: 0106-9543


  34 in total

1.  Severe and protracted cholestasis in 44 young men taking bodybuilding supplements: assessment of genetic, clinical and chemical risk factors.

Authors:  Andrew Stolz; Victor Navarro; Paul H Hayashi; Robert J Fontana; Huiman X Barnhart; Jiezhun Gu; Naga P Chalasani; Maricruz M Vega; Herbert L Bonkovsky; Leonard B Seeff; Jose Serrano; Bharathi Avula; Ikhlas A Khan; Elizabeth T Cirulli; David E Kleiner; Jay H Hoofnagle
Journal:  Aliment Pharmacol Ther       Date:  2019-04-01       Impact factor: 8.171

2.  Epidemiology and carcinogenesis of hepatocellular carcinoma.

Authors:  Trishe Y-M Leong; Anthony S-Y Leong
Journal:  HPB (Oxford)       Date:  2005       Impact factor: 3.647

Review 3.  Sudden cardiac death during anabolic steroid abuse: morphologic and toxicologic findings in two fatal cases of bodybuilders.

Authors:  Vittorio Fineschi; Irene Riezzo; Fabio Centini; Enrico Silingardi; Manuela Licata; Giovanni Beduschi; Steven B Karch
Journal:  Int J Legal Med       Date:  2005-11-15       Impact factor: 2.686

4.  National Athletic Trainers' Association position statement: anabolic-androgenic steroids.

Authors:  Robert D Kersey; Diane L Elliot; Linn Goldberg; Gen Kanayama; James E Leone; Mike Pavlovich; Harrison G Pope
Journal:  J Athl Train       Date:  2012 Sep-Oct       Impact factor: 2.860

Review 5.  Testosterone therapy in men: clinical and pharmacological perspectives.

Authors:  A Gambineri; R Pasquali
Journal:  J Endocrinol Invest       Date:  2000-03       Impact factor: 4.256

6.  Appearance of hepatocellular adenomas on gadoxetic acid-enhanced MRI.

Authors:  Timm Denecke; Ingo G Steffen; Sheela Agarwal; Daniel Seehofer; Thomas Kröncke; Enrique Lopez Hänninen; Incken-Birthe Kramme; Peter Neuhaus; Sanjay Saini; Bernd Hamm; Christian Grieser
Journal:  Eur Radiol       Date:  2012-03-22       Impact factor: 5.315

Review 7.  Clinical value of MRI liver-specific contrast agents: a tailored examination for a confident non-invasive diagnosis of focal liver lesions.

Authors:  Ahmed Ba-Ssalamah; Martin Uffmann; Sanjai Saini; Nina Bastati; Christian Herold; Wolfgang Schima
Journal:  Eur Radiol       Date:  2008-09-23       Impact factor: 5.315

Review 8.  Effects of androgenic-anabolic steroids in athletes.

Authors:  Fred Hartgens; Harm Kuipers
Journal:  Sports Med       Date:  2004       Impact factor: 11.136

9.  Living related liver transplantation in an adult patient with hepatocellular adenoma and carcinoma 13 years after bone marrow transplantation for Fanconi anemia: A case report.

Authors:  Isabelle Colle; Geneviève Laureys; Sarah Raevens; Louis Libbrecht; Juliaan G Leroy; Koen Reyntjens; Anja Geerts; Xavier Rogiers; Roberto I Troisi; Holger Hoehn; Detlev Schindler; Helmut Hanenberg; Vincent De Wilde; Hans Van Vlierberghe
Journal:  Hepatol Res       Date:  2013-05-15       Impact factor: 4.288

10.  The benefits and risks of testosterone replacement therapy: a review.

Authors:  Nazem Bassil; Saad Alkaade; John E Morley
Journal:  Ther Clin Risk Manag       Date:  2009-06-22       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.